ATAGI statements
-
ATAGI statement on the importance and safety of Hepatitis B vaccine at birth.
Australian Technical Advisory Group on Immunisation (ATAGI) advice regarding the importance and safety of Hepatitis B vaccine at birth. -
ATAGI statement on RSV administration errors
Statement on Respiratory Syncytial Virus (RSV) immunisation products and prevention of administration errors. -
ATAGI statement on the administration of COVID-19 vaccines in 2025
Australian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2025. -
ATAGI statement on the administration of seasonal influenza vaccines in 2025
Australian Technical Advisory Group on Immunisation (ATAGI) advice regarding the administration of 2025 seasonal influenza vaccines. -
ATAGI Clinical Guidance on the use of vaccines for the prevention of Mpox
Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on the use of vaccines for the prevention of Mpox in 2024. -
ATAGI statement on the transition from quadrivalent to trivalent seasonal influenza vaccines in Australia
Australian Technical Advisory Group on Immunisation (ATAGI) statement about the transition from quadrivalent to trivalent seasonal influenza vaccines in Australia. -
ATAGI statement on the administration of seasonal influenza vaccines in 2024
Australian Technical Advisory Group on Immunisation (ATAGI) advice regarding the administration of 2024 seasonal influenza vaccines. -
ATAGI statement on the administration of COVID-19 vaccines in 2024
Australian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2024. -
ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine
ATAGI has reviewed the evidence on the intradermal (ID) administration of Japanese encephalitis (JE) vaccines and considered the potential use of Imojev as a dose-sparing mechanism, in the context of the risk of future outbreaks, expanded eligibility in risk areas, and ongoing supply considerations. -
Statement on the clinical use of zoster vaccine in older adults in Australia
This ATAGI clinical statement provides recommendations for the zoster vaccine and Shingrix vaccine.
ATAGI annual statements on immunisation
-
Australian Technical Advisory Group on Immunisation (ATAGI) Annual Statement on Immunisation 2025
The ATAGI 2025 Annual Statement on Immunisation is the fourth publication in this series. The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2024, and includes advice to address key issues for 2025. -
Australian Technical Advisory Group on Immunisation (ATAGI) Annual Statement on Immunisation 2024
The ATAGI 2024 Annual Statement on Immunisation is the fourth publication in this series. The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2023, and includes advice to address key issues for 2024. -
Australian Technical Advisory Group on Immunisation (ATAGI) Annual Statement on Immunisation 2023
The ATAGI 2023 Annual Statement on Immunisation is the third publication in this series. It covers key successes, trends and challenges in the use of vaccines and control of vaccine-preventable diseases in 2023. It also signals ATAGI’s priority actions for addressing key issues for 2023. -
Australian Technical Advisory Group on Immunisation (ATAGI) Annual Statement on Immunisation 2022
The ATAGI 2022 Annual Statement on Immunisation is the second publication in this series, delayed due to COVID-19. It covers key successes, trends and challenges in the use of vaccines and control of vaccine-preventable diseases in 2021. -
Australian Technical Advisory Group on Immunisation (ATAGI) Annual Statement on Immunisation 2021
The ATAGI 2021 Annual Statement on Immunisation is the first publication in this series. It covers key successes, trends and challenges in the use of vaccines and control of vaccine-preventable diseases in 2020. It also signals ATAGI’s priority actions for addressing key issues for 2021 and beyond.
Advice for COVID-19 vaccine providers
The Australian Immunisation Handbook now holds ATAGI's clinical guidance on COVID-19 vaccines. ATAGI also published several supplementary advice documents, which we have collated in this collection.
COVID-19 vaccination – ATAGI clinical advice for COVID-19 vaccine providers
This collection contains resources for health professionals containing advice and guidance on delivering COVID-19 vaccinations. The Australian Technical Advisory Group on Immunisation (ATAGI) wrote these documents.
Date last updated: